Zacks: Analysts Expect Atara Biotherapeutics, Inc. (NASDAQ:ATRA) to Announce -$0.91 Earnings Per Share

Equities research analysts forecast that Atara Biotherapeutics, Inc. (NASDAQ:ATRAGet Rating) will post earnings per share (EPS) of ($0.91) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Atara Biotherapeutics’ earnings. The lowest EPS estimate is ($0.97) and the highest is ($0.79). Atara Biotherapeutics also posted earnings per share of ($0.91) in the same quarter last year. The company is scheduled to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Atara Biotherapeutics will report full-year earnings of ($3.45) per share for the current fiscal year, with EPS estimates ranging from ($3.78) to ($2.96). For the next financial year, analysts forecast that the business will post earnings of ($3.08) per share, with EPS estimates ranging from ($4.08) to ($2.51). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow Atara Biotherapeutics.

Atara Biotherapeutics (NASDAQ:ATRAGet Rating) last announced its earnings results on Thursday, May 5th. The biotechnology company reported ($0.87) earnings per share for the quarter, topping the consensus estimate of ($0.98) by $0.11. Atara Biotherapeutics had a negative net margin of 1,451.79% and a negative return on equity of 122.18%. During the same quarter in the prior year, the business earned ($0.86) earnings per share.

ATRA has been the subject of a number of research reports. HC Wainwright lowered their price target on Atara Biotherapeutics from $31.00 to $29.00 and set a “buy” rating for the company in a research report on Monday, May 23rd. StockNews.com cut Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 17th. The Goldman Sachs Group cut their price objective on Atara Biotherapeutics from $5.00 to $4.00 and set a “sell” rating on the stock in a research note on Tuesday, May 24th. JPMorgan Chase & Co. lowered their target price on Atara Biotherapeutics from $27.00 to $22.00 and set an “overweight” rating for the company in a report on Monday, March 28th. Finally, Canaccord Genuity Group decreased their price objective on Atara Biotherapeutics from $78.00 to $67.00 in a report on Tuesday, March 1st. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Atara Biotherapeutics presently has an average rating of “Hold” and a consensus target price of $26.88.

In related news, CEO Pascal Touchon sold 13,913 shares of the stock in a transaction dated Tuesday, May 17th. The shares were sold at an average price of $5.32, for a total value of $74,017.16. Following the completion of the sale, the chief executive officer now owns 486,313 shares in the company, valued at $2,587,185.16. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Utpal Koppikar sold 5,582 shares of the stock in a transaction dated Tuesday, May 17th. The shares were sold at an average price of $5.32, for a total transaction of $29,696.24. Following the completion of the sale, the chief financial officer now owns 207,592 shares of the company’s stock, valued at approximately $1,104,389.44. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 26,591 shares of company stock worth $141,464. 4.00% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in ATRA. Marshall Wace LLP bought a new position in Atara Biotherapeutics during the first quarter worth about $284,000. Macquarie Group Ltd. raised its stake in shares of Atara Biotherapeutics by 326.1% in the third quarter. Macquarie Group Ltd. now owns 3,311 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 2,534 shares during the last quarter. Trexquant Investment LP bought a new position in shares of Atara Biotherapeutics in the third quarter valued at approximately $488,000. Natixis bought a new position in shares of Atara Biotherapeutics in the third quarter valued at approximately $2,286,000. Finally, Ensign Peak Advisors Inc bought a new position in shares of Atara Biotherapeutics in the third quarter valued at approximately $1,230,000.

Shares of NASDAQ ATRA traded up $0.21 during trading on Wednesday, reaching $5.88. The company had a trading volume of 812,778 shares, compared to its average volume of 1,026,489. The stock has a market capitalization of $549.23 million, a PE ratio of -1.62 and a beta of 1.94. Atara Biotherapeutics has a twelve month low of $4.61 and a twelve month high of $20.04. The stock has a 50-day moving average price of $6.66 and a two-hundred day moving average price of $11.53.

Atara Biotherapeutics Company Profile (Get Rating)

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma.

Featured Stories

Get a free copy of the Zacks research report on Atara Biotherapeutics (ATRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.